ENTA closed +6%; maybe my supposition about DEB025 and EDP-239 is actually valid :- )
HCV stirrings at NVS may also have been responsible for the rally in IDIX (7.85%). I would be surprised if NVS advances the DEB/EDP-239 combo. I'm not sure it's time to reinvent the wheel, with a new HCV DAA class/combo, especially one that has a tarnished safety record. NVS may be reactivating their DEB025 interferon-based studies as a short-duration dosing option in GT2/GT3. Ideally NVS would like to license a nucleotide backbone from IDIX and move forward with a best-in-class NS5A [EDP-239 or IDX-719] with a focus on GT3 coverage. This strategy is obviously up in the air since the [IDIX] IND hold.
Market Data 
Markets 
AI
